Sorrento Therapeutics Stock Could More Than Double, Says Analyst

Sorrento Therapeutics (NASDAQ: SRNE) is an underappreciated coronavirus stock loaded with potential. So loaded, it's poised to double and then some in value.

That's the opinion of one analyst tracking the stock, Mayank Mamtani of B. Riley Securities. Friday morning, B. Riley initiated coverage of the biotech company, tagging it with a buy rating at a price target of $26 per share.

Sorrento has received considerable attention from investors and biotech industry observers for its efforts to combat the coronavirus. Many are keeping an eye on the company's COVI-MSC experimental stem cell therapy that targets COVID-19, the disease caused by the coronavirus. Encouragingly, on Wednesday Sorrento reported quite positive results from a phase 1b study of COVI-MSC.

A researcher studying a sample in a petri dish.

Image source: Getty Images.

While that's a win for the company (albeit only from limited, early stage testing) Mamtani's enthusiastic recommendation is based not only on its coronavirus efforts. He is also impressed with Sorrento's other products in development, which include therapies covering such disparate uses as non-opioid pain relief and immunotherapy, a very active and promising area of biotech at the moment.

These latter development efforts mean that Sorrento is not a one-trick pony. Even if its coronavirus ambitions fall flat -- and they still might, because after all COVI-MSC was put through its paces in a small, early stage trial -- the company has others to fall back on. This, Mamtani wrote in his research note on the stock, makes it "well positioned for success."

The analyst's bullish take added to recent optimism on Sorrento following those COVI-MSC results. On Friday, the company's stock rose by 3.5%, sharply contrasting with the 1.9% decline of the S&P 500 index.

10 stocks we like better than Sorrento Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Sorrento Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of November 20, 2020

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More